PODD · 10-Q · 2026Q3

INSULET CORP

Filed 2026-11-04 · Healthcare · View original filing on EDGAR

Everything PODD's SEC filings said, ranked

Ranked Events

• Share Repurchase ProgramImportance 89 · Surprise 82
  The company repurchased common stock for $300.0 million during the nine months ended September 30, 2026, compared with $59.6 million in the prior-year period. In February 2026, the board extended the existing $125…
• International Omnipod DemandImportance 70 · Surprise 56
  International Omnipod revenue increased 40.8% to $760.8 million for the nine months ended September 30, 2026, including 36.4% growth excluding favorable foreign-exchange effects. Higher sales volumes from a growing…
• Net Income and EPS PerformanceImportance 69 · Surprise 64
  Third-quarter 2026 net income rose 61.1% to $141.1 million from $87.6 million, and diluted EPS increased to $2.03 from $1.24. Nine-month net income more than doubled to $327.1 million from $145.5 million, while diluted…
• Operating Income and MarginsImportance 69 · Surprise 64
  Third-quarter operating income increased 61.3% year over year to $189.8 million, and operating margin expanded to 22.5% from 16.7%. Nine-month operating income grew 34.8% to $441.5 million, with operating margin of…
• Revenue Performance and MixImportance 59 · Surprise 48
  Total revenue for the nine months ended September 30, 2026 increased 25.0% to $2,405.4 million from $1,924.3 million, primarily on higher sales volume from customer-base growth. U.S. Omnipod revenue rose 20.6% to…
• Free Cash FlowImportance 52 · Surprise 56
  Free cash flow was $211.7 million for the nine months ended September 30, 2026, down $117.8 million from $329.5 million in the prior-year period. The decrease primarily reflected higher cash used for working capital…
• Drug Delivery Revenue DeclineImportance 51 · Surprise 64
  Substantially all Drug Delivery revenue comes from Pods sold to Amgen for its Neulasta Onpro kit, which delivers Neulasta to help reduce infection risk after intensive chemotherapy. Drug Delivery revenue fell to $14.6…
• Interest Income TrendsImportance 51 · Surprise 64
  Interest income fell $4.5 million to $4.1 million in the three months ended September 30, 2026, from $8.6 million a year earlier. For the nine months ended September 30, interest income decreased $16.3 million to $12.6…
• Omnipod Quality CorrectionsImportance 46 · Surprise 42
  Insulet issued two voluntary medical device corrections in March and May 2026 for separate manufacturing issues that caused cannula tears in certain Omnipod products. The company recorded a $38.5 million net charge for…
• Operating Cash Flow TrendsImportance 42 · Surprise 40
  Net cash provided by operating activities was $325.7 million for the nine months ended September 30, 2026, versus $386.0 million in the prior-year period. A $177.3 million working-capital outflow included a $179.6…
• Gross Margin DriversImportance 42 · Surprise 40
  Gross margin for the three months ended September 30, 2026 rose to 75.1% from 72.2%, an increase of 280 basis points. Improved manufacturing efficiencies drove the improvement, with a further 90-basis-point benefit…
• Liquidity and Debt PositionImportance 41 · Surprise 22
  Cash and cash equivalents were $584.4 million at September 30, 2026, down from $716.1 million at December 31, 2025; total debt, net, was $962.2 million. The company reported $325.7 million of operating cash flow,…
• Trade Secret LitigationImportance 41 · Surprise 60
  Insulet’s trade-secret case against EOFlow concerned alleged misappropriation of proprietary Omnipod design and manufacturing information; the district court had entered a permanent injunction and reduced the damages…
• Income Tax Rate ChangesImportance 41 · Surprise 48
  The effective tax rate was 20.4% for the third quarter of 2026 and 20.0% for the first nine months, down from 28.7% and 27.0%, respectively, in 2025. Nine-month income tax expense increased to $81.7 million from $53.9…
• Securities Fraud LitigationImportance 40 · Surprise 42
  On July 2, 2026, a putative securities class action was filed in the U.S. District Court for the District of Massachusetts against Insulet and certain current and former executives and directors. The complaint alleges…
• Trade Policy and TariffsImportance 38 · Surprise 24
  Insulet does not expect tariffs to significantly affect gross margin in 2026. The company warns that eliminating the current exemption for certain medical devices would materially affect gross margin and results of…
• Capital Expenditures ProgramImportance 38 · Surprise 24
  Insulet spent $113.9 million on capital expenditures during the nine months ended September 30, 2026, including purchases of machinery, equipment, and tooling for existing manufacturing facilities and investments in…
• Research and Development ExpenseImportance 34 · Surprise 30
  Third-quarter research and development expense increased 18.7% to $91.6 million, while nine-month R&D expense rose 28.2% to $269.4 million. Selling, general and administrative expense increased 11.3% to $350.7 million…
• Supply Chain and InventoryImportance 32 · Surprise 24
  Insulet reported a $103.0 million increase in inventories during the nine months ended September 30, 2026. The increase was primarily attributable to a planned inventory build to satisfy anticipated demand and advance…
• Omnipod Product DevelopmentImportance 31 · Surprise 42
  Insulet continued investment in Omnipod and pipeline products during the nine months ended September 30, 2026. Named development programs include Omnipod 6, described as the next-generation automated insulin delivery…

Revenue by Product (in millions)

Revenue by Geography (in millions)